Literature DB >> 36262902

Arterial and Venous Thrombosis From Delayed-Onset Heparin-Induced Thrombocytopenia.

Abhinandan R Chittal1, Ajay Kumar1, Shiavax J Rao1, Pallavi Lakra1, Natalia Nacu1.   

Abstract

Heparin Induced Thrombocytopenia (HIT) is a life threatening condition which is caused due to antibody formation following exposure to heparin or heparin products. It occurs due to the formation of Platelet Factor 4 antibodies (PF4). HIT is classified into 3 categories based on the duration between heparin exposure and onset of drop in platelet counts. A less common form of HIT is delayed onset HIT which occurs more than 9 days after exposure to heparin or heparin products. In this report we would like to present a rare case of delayed onset HIT which occurred in our patient who presented with rhabdomyolysis and Non ST elevation myocardial infraction (NSTEMI); which resulted in limb ischemia which needed to be treated by amputation of the affected area. We also highlight further management of patients who have thrombotic disease in the setting of HIT and review literature of how heparin or heparin products can be reintroduced in such patient who cannot be managed by other anticoagulation.
© 2022 Greater Baltimore Medical Center.

Entities:  

Keywords:  Delayed onset HIT; HIT; Heparin induced thrombocytopenia; NSTEMI; Rhabdomyolysis

Year:  2022        PMID: 36262902      PMCID: PMC9533806          DOI: 10.55729/2000-9666.1081

Source DB:  PubMed          Journal:  J Community Hosp Intern Med Perspect        ISSN: 2000-9666


  19 in total

1.  White clot syndrome.

Authors:  P E Stanton; J R Evans; A A Lefemine; N M Vo; G A Rannick; C V Morgan; P J Hinton; M Read
Journal:  South Med J       Date:  1988-05       Impact factor: 0.954

2.  Temporal aspects of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

Review 3.  Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia. A systematic review of 54 reported cases.

Authors:  Joseph J Shatzel; Meg Crapster-Pregont; Thomas G Deloughery
Journal:  Thromb Haemost       Date:  2016-04-14       Impact factor: 5.249

4.  Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations.

Authors:  G R Rhodes; R H Dixon; D Silver
Journal:  Surg Gynecol Obstet       Date:  1973-03

5.  Impact of the patient population on the risk for heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J A Sheppard; P Horsewood; P J Simpson; J C Moore; J G Kelton
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

6.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Gowthami M Arepally; Beng H Chong; Douglas B Cines; Andreas Greinacher; Yves Gruel; Lori A Linkins; Stephen B Rodner; Sixten Selleng; Theodore E Warkentin; Ashleigh Wex; Reem A Mustafa; Rebecca L Morgan; Nancy Santesso
Journal:  Blood Adv       Date:  2018-11-27

Review 7.  Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome.

Authors:  Theodore E Warkentin; William C Aird; Jacob H Rand
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2003

8.  Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; C P Hayward; L K Boshkov; A V Santos; J A Sheppard; A P Bode; J G Kelton
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

9.  The multiple complexes formed by the interaction of platelet factor 4 with heparin.

Authors:  P E Bock; M Luscombe; S E Marshall; D S Pepper; J J Holbrook
Journal:  Biochem J       Date:  1980-12-01       Impact factor: 3.857

10.  Heparin induced thrombocytopenia: case presentation and review.

Authors:  Ronny A Cohen; Mariely Castellano; Christine A Garcia
Journal:  J Clin Med Res       Date:  2012-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.